VIRMA (Virus-Induced RNA Methyltransferase Associated protein), also known as KIAA1429, is a key component of the N6-methyladenosine (m6A) methyltransferase complex that catalyzes the most prevalent internal modification of messenger RNA in eukaryotic cells[1]. This large protein (approximately 1,500 amino acids) plays a critical role in regulating RNA metabolism through its involvement in m6A deposition, which affects RNA splicing, stability, translation, and subcellular localization[2].
The protein is encoded by the KIAA1429 gene (also called VIRMA or Virmatin), located on chromosome 18q21.1 in humans. It is highly conserved across species and is expressed in various tissues, with particularly high expression in the brain, indicating important functions in neuronal cells.
VIRMA is a modular protein containing several functional domains:
The protein lacks canonical methyltransferase activity itself but serves as a scaffold that coordinates the assembly and function of the m6A methyltransferase complex[1:1].
VIRMA is a core component of the "m6A writer" complex, which includes[2:1]:
VIRMA specifically mediates the interaction between the catalytic core (METTL3/METTL14) and the regulatory components (WTAP), ensuring proper complex formation and targeting to specific RNA substrates[1:2].
N6-methyladenosine (m6A) is the most abundant internal modification of messenger RNA in eukaryotes, occurring on average at 1-3 sites per mRNA molecule[3]. This modification is dynamic and reversible, regulated by "writers" (methyltransferases), "readers" (methylation-sensitive binding proteins), and "erasers" (demethylases)[4].
Key functions of m6A include:
The m6A machinery operates through a coordinated system[2:2]:
Writers (Methyltransferases):
Readers (M6A-binding proteins):
Erasers (Demethylases):
VIRMA's role in m6A modification directly impacts multiple aspects of RNA processing:
VIRMA shows preferential targeting of:
The specificity of m6A deposition is determined by the combined action of METTL3/METTL14 substrate recognition and VIRMA-mediated complex positioning.
Emerging research demonstrates critical roles for m6A modification in brain development, neuronal function, and neurodegenerative diseases[6]:
While direct evidence linking VIRMA to specific neurodegenerative diseases is still emerging, the broader m6A pathway has been implicated in:
Multiple neurodegenerative diseases are characterized by RNA metabolism defects:
VIRMA-mediated m6A modifications may contribute to these RNA metabolism defects through:
Recent studies have shown that VIRMA modulates photoreceptor cell function through m6A modification, linking RNA methylation to retinal degeneration[9]. This suggests VIRMA may play a role in maintaining photoreceptor viability, with implications for understanding neurodegeneration in the retina and potentially the brain.
The m6A pathway represents a potential therapeutic target for neurodegenerative diseases[10]:
Future research should focus on:
Liu J, et al. VIRMA mediates m6A deposition in RNA. Nature Communications. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Yue Y, et al. m6A writer complex: structure and function. Trends in Cell Biology. 2020. ↩︎ ↩︎ ↩︎
Dominissini D, et al. Topology of the human m6A epitranscriptome. Nature. 2012. ↩︎ ↩︎
Roundtree IA, et al. Dynamic m6A modification in RNA metabolism. Cell. 2017. ↩︎
Shi H, et al. m6A erasure by FTO. Cell. 2012. ↩︎
Zhao BS, et al. m6A-dependent pathway in synaptic plasticity and learning. Nature Neuroscience. 2021. ↩︎
Zhang C, et al. m6A modification in Alzheimer's disease. Cell Reports. 2023. ↩︎
Huang H, et al. m6A in Parkinson's disease models. Acta Neuropathologica. 2024. ↩︎
Wang X, et al. m6A in photoreceptor function and retinal degeneration. Cell Reports. 2024. ↩︎
Chen J, et al. Targeting m6A readers and writers in disease therapy. Nature Reviews Drug Discovery. 2024. ↩︎